Amgen restructures to focus resources on late-stage drugs

10/19/2011 | Los Angeles Times (tiered subscription model)

Amgen said it is eliminating about 380 positions in research and development to focus resources on its late-stage drug pipeline. "It's very expensive to conduct clinical trials," said spokeswoman Mary Klem. "The patient population gets bigger at each phase. That's the crux of what is causing us to make these strategic changes."

View Full Article in:

Los Angeles Times (tiered subscription model)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Director of Operations - GBS
Mayo Clinic
Rochester, MN
Health Plan CEO – Oregon
Trillium Community Health Plan
Eugene, OR
Chief Executive Officer
CarePoint Health Plan
Jersey City, NJ
Senior Vice President, Clinical Affairs & Strategic Partnerships
America's Health Insurance Plans (AHIP)
Washington, DC